10 Best Vanguard Funds to Buy Right Now
https://www.fool.com/investing/2024/05/27/10-best-vanguard-funds-to-buy-right-now/?source=iedfolrf0000001
May 27, 2024 - These 10 Vanguard stock ETFs can help you build a top-notch portfolio.
0
5 Magnificent Stocks Being Bought for Warren Buffett's $646 Million "Secret" Portfolio
https://www.fool.com/investing/2024/05/27/5-stocks-bought-warren-buffett-secret-portfolio/?source=iedfolrf0000001
May 27, 2024 - Warren Buffett's secret portfolio contains 90 securities -- five of which are phenomenal businesses whose shares were purchased in the March-ended quarter.
0
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
https://www.zacks.com/stock/news/2278966/johnson-johnson-jnj-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2278966
May 24, 2024 - In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $146.97, denoting a -1.82% change from the preceding trading day.
0
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
https://www.zacks.com/stock/news/2277543/lilly-lly-hits-record-high-on-crohn-s-disease-study-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2277543
May 22, 2024 - Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.
0
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
https://www.zacks.com/stock/news/2275581/j-j-jnj-to-boost-dermatology-portfolio-with-new-acquisition?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2275581
May 17, 2024 - Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
0
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
https://www.zacks.com/stock/news/2275562/pharma-stock-roundup-bayry-s-q1-earnings-jnj-s-new-buyout-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2275562
May 17, 2024 - Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
0
1 No-Brainer Growth Stock to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/05/15/1-no-brainer-growth-stock-to-buy-and-hold-for-10/?source=iedfolrf0000001
May 15, 2024 - This company's potential far outweighs its risks.
0
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
https://www.zacks.com/stock/news/2271674/teva-q1-earnings-miss-schizophrenia-study-meets-goal-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2271674
May 09, 2024 - TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
0
Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix
https://www.zacks.com/commentary/2269663/q1-earnings-season-scorecard-and-fresh-analyst-reports-for-tesla-jnj-netflix?cid=CS-ZC-FT-research_daily-2269663
May 07, 2024 - Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.
0
A Look at Pharma ETFs Post Q1 Earnings
https://www.zacks.com/stock/news/2269782/a-look-at-pharma-etfs-post-q1-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2269782
May 07, 2024 - Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
0